ESC Premium Access

Transcatheter Aortic Valve Replacement in Low-Risk Patients – Represented in NEJM by the PARTNER 3 and Evolut Low Risk trials.

Congress Presentation

About the speaker

Doctor Michael Mack

Baylor Scott & White Health, Dallas (United States of America)
4 presentations
0 follower

2 more presentations in this session

Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.

Speaker: Professor C. Rapezzi (Ferrara, IT)


Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).

Speaker: Professor J. Mcneil (Melbourne, AU)


Access the full session

Highlights from the New England Journal of Medicine: editors’ choice

Speakers: Doctor M. Mack, Professor C. Rapezzi, Professor J. Mcneil

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb